Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for ...
MarketScreener

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Three scientific presentations will highlight new analyses of VOQUEZNA ® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in ...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of ...

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates ...

Alpha Cognition to Present New ZUNVEYL® (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced t ...

What Are Hair Supplements? | The Role of Nutrients and What They Can and Cannot Do

"I want to take supplements that are good for my hair," or "I'm worried about hair loss, so I want to rethink my nutrition." ...

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week ...

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic ...

U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients ...

1 In 5 Seniors At Risk For Dangerous Drug Interactions

By Dennis Thompson HealthDay ReporterMONDAY, Sept. 28, 2026 (HealthDay News) — More than 1 in 5 seniors are at risk for a potentially dangerous drug interaction from the medications they’ve been ...
Medical Xpress

Older Americans are taking more medications, with 1 in 5 at risk for a major drug interaction

Older Americans are increasingly taking multiple prescription medications and dietary supplements. Although the prevalence of potentially major drug-drug interactions has declined slightly, more than ...
MedPage Today

Possible Drug-Drug Interactions Flagged for Older Americans

A cross-sectional study analyzed the changing use of medications and dietary supplements in the U.S. between 2015-2016 and 2021-2023. Polypharmacy involving prescription medications and dietary ...
MarketScreener

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

EXXUA net revenue was $6.6 million during fiscal 2026. EXXUA was made commercially available in mid-December 2025, and more formally launched in mid-January 2026 following the completion of sales ...
RAPS

EMA guideline addresses concerns with potential drug interactions in the GI tract

The European Medicines Agency (EMA) has published a guideline on evaluating drug interactions in the gastrointestinal tract that addresses situations in which extrinsic factors in the gastrointestinal ...